Most Read Articles
12 Jun 2018
Percutaneous coronary intervention (PCI) is a safe procedure to perform on obese and morbidly obese patients, a recent study has shown.
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

4 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
4 days ago
Use of quetiapine among critically ill patients rarely leads to corrected QT (QTc) interval prolongation, reports a new study.

Rituximab may induce remission, allow glucocorticoid tapering in IgAV

06 Dec 2017

Rituximab appears to be safe and effective in the treatment of patients with adult-onset IgA vasculitis (IgAV), inducing disease remission and allowing glucocorticoid tapering, according to a study.

The multicentre, observational study included 22 patients with adult-onset IgAV (formerly Henoch-Schönlein purpura) who had received rituximab for either refractory/relapsing disease or due to contraindications to conventional glucocorticoid/immunosuppressive therapy. The median follow-up was 24 months.

Researchers estimated the rates of remission (defined on the basis of the Birmingham Vasculitis Activity Score, BVAS) and relapse, as well as the variations over time in estimated glomerular filtration rate (eGFR), proteinuria, C-reactive protein levels, BVAS and prednisone dose.

Rituximab was given to 16 patients as add-on therapy and to six as monotherapy. Overall, 20 (90.9 percent) achieved remission and seven (35 percent) subsequently relapsed. Rituximab treatment led to a significant reduction in 24 hour-proteinuria (p<0.0001), C-reactive protein (p=0.0005), BVAS (p<0.0001) and prednisone dose (p<0.0001). Moreover, eGFR remained stable.

In terms of safety, treatment was well tolerated. There was one patient who died after 60 months of follow-up.

Researchers noted that while the use of rituximab in IgAV may potentially reduce the proliferation of IgA-producing plasma cells or deplete tissue-infiltrating B-cells, “its therapeutic efficacy most likely results from the impairment of other B-cell functions such as antigen-presentation and T-cell costimulation, as already postulated in ANCA-associated vasculitis and other autoimmune conditions.” [Nephrol Dial Transplant 2013;29:1151–59]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2018
Percutaneous coronary intervention (PCI) is a safe procedure to perform on obese and morbidly obese patients, a recent study has shown.
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

4 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
4 days ago
Use of quetiapine among critically ill patients rarely leads to corrected QT (QTc) interval prolongation, reports a new study.